Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 247

1.

Editorial commentary: environmental risk factors for Pneumocystis pneumonia hospitalization in HIV/AIDS patients.

Hughes WT.

Clin Infect Dis. 2013 Jan;56(1):82-3. doi: 10.1093/cid/cis846. Epub 2012 Oct 5. No abstract available.

PMID:
23042977
2.

Healthcare-Associated Infections at a Children's Cancer Hospital, 1983-2008.

McCullers JA, Williams BF, Wu S, Smeltzer MP, Williams BG, Hayden RT, Howard SC, Pui CH, Hughes WT.

J Pediatric Infect Dis Soc. 2012 Mar;1(1):26-34. doi: 10.1093/jpids/pis034. Epub 2012 Mar 1.

3.

Pneumocystis Carinii.

Hughes WT.

In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 85.

4.

Transmission of Pneumocystis species among renal transplant recipients.

Hughes WT.

Clin Infect Dis. 2007 May 1;44(9):1150-1. Epub 2007 Mar 26. No abstract available.

PMID:
17407030
5.

Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia.

Madden RM, Pui CH, Hughes WT, Flynn PM, Leung W.

Cancer. 2007 Apr 15;109(8):1654-8.

6.

Systemic antifungal therapy: Past, present and future.

Al-Mohsen I, Hughes WT.

Ann Saudi Med. 1998 Jan-Feb;18(1):28-38. No abstract available.

7.

Pneumocystis carinii versus Pneumocystis jirovecii (jiroveci) Frenkel.

Hughes WT.

Clin Infect Dis. 2006 Apr 15;42(8):1211-2; author reply 1212-4. No abstract available.

PMID:
16575751
8.

Should prophylactic antibiotics be used in afebrile neutropenic oncology patients?

Hughes WT.

Nat Clin Pract Oncol. 2006 Mar;3(3):130-1. No abstract available.

PMID:
16520800
9.

Bloodstream infections in cancer patients.

Hughes WT.

Eur J Cancer. 2005 Jul;41(10):1370-1. No abstract available.

PMID:
15913985
10.

Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.

Hughes WT, Dankner WM, Yogev R, Huang S, Paul ME, Flores MA, Kline MW, Wei LJ; Pediatric AIDS Clinical Trials Group 254 Team.

Clin Infect Dis. 2005 Jan 1;40(1):136-45. Epub 2004 Dec 6.

PMID:
15614703
11.

Pneumocystis carinii vs. Pneumocystis jiroveci: another misnomer (response to Stringer et al.).

Hughes WT.

Emerg Infect Dis. 2003 Feb;9(2):276-7; author reply 277-9. No abstract available.

12.

Effects of immunomodulators on acute Trypanosoma Cruzi infection in mice.

Oz HS, Hughes WT, Thomas EK, McClain CJ.

Med Sci Monit. 2002 Jun;8(6):BR208-11.

PMID:
12070425
13.

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS.

Clin Infect Dis. 2002 Mar 15;34(6):730-51. Epub 2002 Feb 13. No abstract available.

PMID:
11850858
14.
15.

Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants.

Vargas SL, Hughes WT, Santolaya ME, Ulloa AV, Ponce CA, Cabrera CE, Cumsille F, Gigliotti F.

Clin Infect Dis. 2001 Mar 15;32(6):855-61. Epub 2001 Mar 9.

PMID:
11247708
16.

Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer.

Shenep JL, Flynn PM, Baker DK, Hetherington SV, Hudson MM, Hughes WT, Patrick CC, Roberson PK, Sandlund JT, Santana VM, Sixbey JW, Slobod KS.

Clin Infect Dis. 2001 Jan;32(1):36-43. Epub 2000 Dec 8.

PMID:
11112678
17.

A rat model for combined Trypanosoma cruzi and Pneumocystis carinii infection.

Oz HS, Hughes WT, Varilek GW.

Microb Pathog. 2000 Dec;29(6):363-5.

PMID:
11095921
18.

Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model.

Oz HS, Hughes WT, Rehg JE, Thomas EK.

Microb Pathog. 2000 Sep;29(3):187-90.

PMID:
10968950
19.

Mycobacterial infections in bone marrow transplant recipients.

Hughes WT.

Biol Blood Marrow Transplant. 2000;6(4):359-60. No abstract available.

20.

Search for Pneumocystis carinii DNA in upper and lower respiratory tract of humans.

Oz HS, Hughes WT.

Diagn Microbiol Infect Dis. 2000 Jul;37(3):161-4.

PMID:
10904188
21.

Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers.

Vargas SL, Ponce CA, Gigliotti F, Ulloa AV, Prieto S, Muñoz MP, Hughes WT.

J Clin Microbiol. 2000 Apr;38(4):1536-8.

22.

Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials Group.

Hughes WT, Shenep JL, Rodman JH, Fridland A, Willoughby R, Blanchard S, Purdue L, Coakley DF, Cundy KC, Culnane M, Zimmer B, Burchett S, Read JS.

Antimicrob Agents Chemother. 2000 Apr;44(4):1041-6.

23.

Association of primary Pneumocystis carinii infection and sudden infant death syndrome.

Vargas SL, Ponce CA, Hughes WT, Wakefield AE, Weitz JC, Donoso S, Ulloa AV, Madrid P, Gould S, Latorre JJ, Avila R, Benveniste S, Gallo M, Belletti J, Lopez R.

Clin Infect Dis. 1999 Dec;29(6):1489-93.

PMID:
10585801
24.

Aspergillosis in children with cancer: A 34-year experience.

Abbasi S, Shenep JL, Hughes WT, Flynn PM.

Clin Infect Dis. 1999 Nov;29(5):1210-9.

PMID:
10524965
25.
26.

Rat model for dual opportunistic pathogen prophylaxis: Cryptosporidium parvum and Pneumocystis carinii.

Oz HS, Hughes WT, Rehg JE.

Lab Anim Sci. 1999 Jun;49(3):331-4. No abstract available.

PMID:
10403453
27.

Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team.

Ngo LY, Yogev R, Dankner WM, Hughes WT, Burchett S, Xu J, Sadler B, Unadkat JD.

Antimicrob Agents Chemother. 1999 Jun;43(6):1516-9.

28.

Current issues in the epidemiology, transmission, and reactivation of Pneumocystis carinii.

Hughes WT.

Semin Respir Infect. 1998 Dec;13(4):283-8. Review.

PMID:
9872624
29.

Prologue to AIDS. The recognition of infectious opportunists.

Hughes WT.

Medicine (Baltimore). 1998 Jul;77(4):227-32. No abstract available.

30.

Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review.

Hughes WT.

Clin Infect Dis. 1998 Jul;27(1):191-204. Review.

PMID:
9675476
31.

Amprenavir : A Viewpoint by Walter T. Hughes.

Hughes WT.

Drugs. 1998 Jun;55(6):844. doi: 10.2165/00003495-199855060-00017. No abstract available.

PMID:
27518724
32.

Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia.

Hughes WT, Sillos EM, LaFon S, Rogers M, Woolley JL, Davis C, Studenberg S, Pattishall E, Freeze T, Snyder G, Staton S.

J Infect Dis. 1998 Apr;177(4):1046-56.

PMID:
9534981
33.

Disseminated infection due to Mycobacterium fortuitum in a patient with desmoid tumor.

Choueiry MA, Scurto PL, Flynn PM, Rao BN, Hughes WT.

Clin Infect Dis. 1998 Jan;26(1):237-8. No abstract available.

PMID:
9455572
34.

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.

Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS.

Clin Infect Dis. 1997 Sep;25(3):551-73. Review.

PMID:
9314442
35.

Pneumocystis carinii infection alters GTP-binding proteins in the lung.

Oz HS, Hughes WT.

J Parasitol. 1997 Aug;83(4):679-85.

PMID:
9267411
36.

Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.

Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, Synold T, Relling MV, Ribeiro RC, Crist WM, Evans WE.

N Engl J Med. 1997 Jun 19;336(25):1781-7.

38.

The athlete: an immunocompromised host.

Hughes WT.

Adv Pediatr Infect Dis. 1997;13:79-99. Review. No abstract available.

PMID:
9544308
39.

Efficacy of lasalocid against murine Pneumocystis carinii pneumonitis.

OZ HS, Hughes WT, Rehg JE.

Antimicrob Agents Chemother. 1997 Jan;41(1):191-2.

40.

Helicobacter pylori infection.

Hughes WT.

Pediatr Ann. 1996 Sep;25(9):491-3. No abstract available.

PMID:
8880881
41.

Acute fulminating babesiosis in hamsters infected with Babesia microti.

Oz HS, Hughes WT.

Int J Parasitol. 1996 Jun;26(6):667-70.

PMID:
8875313
42.

Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia.

Hughes WT, Killmar J.

Antimicrob Agents Chemother. 1996 Apr;40(4):962-5.

43.

Search for extrapulmonary Pneumocystis carinii in an animal model.

Oz HS, Hughes WT, Vargas SL.

J Parasitol. 1996 Apr;82(2):357-9.

PMID:
8604119
44.

Effect of sex and dexamethasone dose on the experimental host for Pneumocystis carinii.

Oz HS, Hughes WT.

Lab Anim Sci. 1996 Feb;46(1):109-10. No abstract available.

PMID:
8699805
45.

Recent advances in the prevention of pneumocystis carinii pneumonia.

Hughes WT.

Adv Pediatr Infect Dis. 1996;11:163-86. Review. No abstract available.

PMID:
8718463
46.

Successful prevention and treatment of babesiosis with atovaquone.

Hughes WT, Oz HS.

J Infect Dis. 1995 Oct;172(4):1042-6.

PMID:
7561178
47.

Pneumocystis in infants and children.

Hughes WT.

N Engl J Med. 1995 Aug 3;333(5):320-1. No abstract available.

PMID:
7596383
48.

Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.

Simonds RJ, Hughes WT, Feinberg J, Navin TR.

Clin Infect Dis. 1995 Aug;21 Suppl 1:S44-8. Review.

PMID:
8547511
49.

Limited persistence in and subsequent elimination of Pneumocystis carinii from the lungs after P. carinii pneumonia.

Vargas SL, Hughes WT, Wakefield AE, Oz HS.

J Infect Dis. 1995 Aug;172(2):506-10.

PMID:
7622894
50.

Supplemental Content

Loading ...
Support Center